Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
Date:9/14/2007

on for future payments to Palatin, other than for previously

incurred costs not yet reimbursed and approved expense reimbursements

related to the wind-down of the collaboration.

-- Advancement of a lead compound through the preclinical stages resulting

in the anticipated filing of an Investigational New Drug Application

for a synthetic compound that mimics natriuretic peptides for the

treatment of patients with congestive heart failure in the second half

of calendar year 2007.

-- The completion of an exploratory at-home Phase 2B clinical trial in

pre- and postmenopausal women. We are in the final stages of compiling

the data and anticipate releasing the results of this trial later this

month.

LICENSE, GRANTS AND CONTRACTS

For the quarter ended June 30, 2007, Palatin recognized revenue under its collaboration agreement with King of $1.8 million, which includes King's share of bremelanotide development costs, and $0.7 million of contract revenue related to its February 2007 collaboration with AstraZeneca. In the comparable quarter of 2006, Palatin recognized $4.9 million of contract revenue from King, reflecting significantly higher cost reimbursement revenue resulting from Palatin's clinical study activities.

COSTS AND EXPENSES

Total operating expenses for the quarter ended June 30, 2007 were $9.1 million versus $13.2 million for the comparable quarter of 2006, reflecting lower development costs of bremelanotide following the completion of two Phase 2B clinical trials in patients with ED, which were partially offset by other research and development spending and higher stock-based compensation charges.

CASH POSITION

Palatin's cash, cash equivalents and investments totaled $33.8 million as of June 30, 2007, compared to $30.7 million at June 30, 2006, as current year operating expenses were largely offset by net proceeds from the February 200
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... (PRWEB) August 27, 2014 In ... through Lawrence Livermore National Security LLC ... develop and deliver a state-of-the-art laser system for ... (ELI Beamlines), under construction in the Czech Republic. ... the laser system, called the " High repetition-rate ...
(Date:8/27/2014)... 27, 2014 The Global and China ... on the current state of the Trifluoroacetic Acid industry ... basic overview of the industry, including definitions, applications and ... market analysis are provided with a focus on history, ... comparison between the international and Chinese situation is also ...
(Date:8/27/2014)... Aug. 27, 2014  A novel biomarker for ... physicians better identify early-stage disease, when treatment can ... to a new study in The Journal of ... DGX ) and other institutions found ... outperformed conventional antibody-serum testing, including rheumatoid factor (RF) ...
(Date:8/27/2014)... 27, 2014 Flagship Biosciences LLC, a ... to the pharmaceutical and medical device industries, has announced ... fast growing company has consolidated its histology and tissue ... to Westminster, CO, just north of Denver. The ... W. 103rd Ave., Suite 100, Westminster, CO 80021 , ...
Breaking Biology Technology:LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4Flagship Biosciences Announces Relocation and Expansion 2
... SAN DIEGO, Jan. 26 Amylin Pharmaceuticals, Inc.,(Nasdaq: ... P. Mihalik has been appointed,Senior Vice President, Sales ... more than 30 years of experience across multiple ... management,product launches and brand management. His career has ...
... and BINGHAM FARMS, Mich., Jan. 26 WellCentive, ... by my1HIE(sm) (My,One Health Information Exchange) as its ... Through the use of WellCentive Registry, ... providers in Southeast Michigan will be better able ...
... Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical ... for ganciclovir ophthalmic gel, 0.15%, has been accepted for ... Sirion Therapeutics is seeking approval for ganciclovir as a ... the herpes simplex virus. The FDA has issued an ...
Cached Biology Technology:Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer 2Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer 3my1HIE(sm) Implements WellCentive Registry 2my1HIE(sm) Implements WellCentive Registry 3Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes 2Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes 3
(Date:8/27/2014)... that a single fungal cell or bacterial colony exerts on ... a heavy role in setting up some of the most ... be too much of a stretch to say that plants ... respond to the touch of beneficial fungi, according to a ... at the University of Wisconsin-Madison. , "Many people have ...
(Date:8/27/2014)... mysteries of the human genome was unveiled today in ... detailed comparison yet of how the genomes of the ... research, appearing August 28 in in the journal ... three species, genomes is "read out," and how their ... results add billions of entries to a publicly available ...
(Date:8/27/2014)... have identified a gene that could help scientists engineer ... in the cell membrane of plants that senses changes ... machinery accordingly. , "It,s similar to a thermostat," ... Duke. , The findings, which appear Aug. 28 ... easier to feed the world,s growing population in the ...
Breaking Biology News(10 mins):A touching story: The ancient conversation between plants, fungi and bacteria 2A touching story: The ancient conversation between plants, fungi and bacteria 3Encyclopedia of how genomes function gets much bigger 2Encyclopedia of how genomes function gets much bigger 3Encyclopedia of how genomes function gets much bigger 4Water 'thermostat' could help engineer drought-resistant crops 2
... 27, 2013) A team of Korean ... the neurobehavioral function of six week-old mice ... to treat hypoxic-ischemic brain injury, and found that ... through exercise-induced fibroblast growth factor 2 (FGF2), a ...
... Researchers from Lund University, Yale University and the University of ... cuckolded males in many species still provide paternal care. When ... successful. In many species males put a lot of ... At first glance this makes no sense at all because ...
... Since its introduction fifty or so years ago, thermography has ... lameness in horses. The method is fast and safe ... body surface emits infrared radiation that can be detected by ... use. The camera produces a coloured image that shows ...
Cached Biology News:Environmental enrichment important factor impacting cell transplantation and brain repair 2Environmental enrichment important factor impacting cell transplantation and brain repair 3Why sticking around is sometimes the better choice 2Blowing in the wind: How accurate is thermography of horses' legs? 2
S-100A10 (H-80)...
Vapor phase risers are available in various heights to accomodate a variety of inventory solutions. Risers are used to creat a false bottom in which the tanks platform rests and Liquid nitrogen is s...
... single-stranded DNA and RNA endonucleolytically to ... (DNA:DNA, DNA:RNA or RNA:RNA) are resistant ... concentrations of enzyme (1). The enzyme ... from double-stranded DNA (2), for selective ...
SP6 RNA Polymerase, 50 l, 20 U/l ,Cap Scribe Buffer, 100 l, 5x conc....
Biology Products: